Baird Starts Coherus Biosciences (CHRS) at Outperform

October 18, 2016 4:05 PM EDT Send to a Friend
Baird initiates coverage on Coherus Biosciences (NASDAQ: CHRS) with a Outperform rating and a price target of $40.00.Analyst Michael Ulz ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login